Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Pinato

Showing results (211-220 of 238) with videos related to

Pageof 24
Sort By:
Clinical Genitourinary Cancer|July 1, 2022
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial CarcinomaDimitrios Makrakis, Rafee Talukder, Genevieve Ihsiu Lin, et al.
Journal for Immunotherapy of Cancer|April 8, 2021
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapyAlessio Cortellini, Massimo Di Maio, Olga Nigro, et al.
Clinical Genitourinary Cancer|September 26, 2022
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial CarcinomaRafee Talukder, Dimitrios Makrakis, Genevieve Ihsiu Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with CancerAlessio Cortellini, Antonio D'Alessio, Siobhan Cleary, et al.
Journal for Immunotherapy of Cancer|March 23, 2021
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory ScoreGino M Dettorre, Saoirse Dolly, Angela Loizidou, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 24, 2022
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort StudySergio Muñoz-Martínez, Victor Sapena, Alejandro Forner, et al.
JHEP Reports : Innovation in Hepatology|March 10, 2025
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumabSimon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, et al.
The Lancet. Digital Health|February 13, 2026
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort studyMathew Vithayathil, Giulia Francesca Manfredi, Antonio D'Alessio, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2021
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapySebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Therapeutic Advances in Medical Oncology|November 15, 2021
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registryLaia Garrigós, Cristina Saura, Clara Martinez-Vila, et al.
Pageof 24

Showing results (211-220 of 238) with videos related to

Sort By:
Pageof 24
Clinical Genitourinary Cancer|July 1, 2022
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial CarcinomaDimitrios Makrakis, Rafee Talukder, Genevieve Ihsiu Lin, et al.
Journal for Immunotherapy of Cancer|April 8, 2021
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapyAlessio Cortellini, Massimo Di Maio, Olga Nigro, et al.
Clinical Genitourinary Cancer|September 26, 2022
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial CarcinomaRafee Talukder, Dimitrios Makrakis, Genevieve Ihsiu Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with CancerAlessio Cortellini, Antonio D'Alessio, Siobhan Cleary, et al.
Journal for Immunotherapy of Cancer|March 23, 2021
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory ScoreGino M Dettorre, Saoirse Dolly, Angela Loizidou, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 24, 2022
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort StudySergio Muñoz-Martínez, Victor Sapena, Alejandro Forner, et al.
JHEP Reports : Innovation in Hepatology|March 10, 2025
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumabSimon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, et al.
The Lancet. Digital Health|February 13, 2026
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort studyMathew Vithayathil, Giulia Francesca Manfredi, Antonio D'Alessio, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2021
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapySebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Therapeutic Advances in Medical Oncology|November 15, 2021
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registryLaia Garrigós, Cristina Saura, Clara Martinez-Vila, et al.
Pageof 24